BFLY Reaches 20-Day High Amid Insider Buying Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 24 Nov 25
Source: Coinmarketcap
Shares of Butterfly Network (BFLY.N) surged today, reaching a 20-day high as the stock gained 6.04% following positive developments in insider trading. Notably, Larry Robbins acquired 2.8 million shares at $2.42 each, marking his first purchase in a year and reflecting confidence in the company's future. The uptick in share price was further bolstered by the announcement that CEO Joseph DeVivo and Interim CFO Megan Carlson will present at the Evercore Healthcare Conference, showcasing their innovative handheld ultrasound technology. Despite ongoing challenges, including an adjusted EBITDA loss of $8.1 million, the recent momentum indicates a potential shift in investor sentiment towards Butterfly Network.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFLY is 4.25 USD with a low forecast of 4.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.310
Low
4.00
Averages
4.25
High
4.50
Current: 4.310
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
